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Melanoma is one of the most common cancers in the United States and 
worldwide. The incidence rates of melanoma continue to rise rapidly, especially over the 
past few decades. Although targeted therapies and immunotherapy have shown 
promise in the management of advanced melanoma, the acquired resistance in some 
patients emerges as a major hurdle within the clinic. Wnt5A has been identified as a 
potential molecular target due to its important role in melanoma progression and 
therapeutic resistance. It is believed that Wnt5A can regulate the secretion of 
inflammatory cytokines and chemokines that are involved in leukocyte trafficking. The 
mechanisms underlying the establishment of immune resistance by Wnt5A in the 
context of melanoma are not well understood. Here, we demonstrated that melanoma-
derived Wnt5A downregulates the expression of inflammatory chemokines: CXCL10, 
which mediates immune responses by recruiting lymphocytes through the CXCR3 
receptor; and CCL2, which binds to CCR2 and drives chemotaxis of monocytes. Levels 
of inflammatory cytokines, IFN-γ and TNF-α, were also reduced by Wnt5A, creating a 
less immunogenic microenvironment. The treatment of melanoma cells with 
recombinant Wnt5A reduced infiltration of macrophages and dendritic cells into the 
primary tumor site, owing to the reduced CCL2/CCR2 signaling. Finally, our immune 
profiling analysis via flow cytometry provided us with an optimized method of thoroughly 
investigating the effects of cancer-derived Wnt5A in the infiltration of immune 
populations. Together with the expression patterns of chemokine receptors: CXCR3 and 
CCR2 on the identified leukocytes, it would profoundly impact our future studies on 
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Wnt5A-mediated chemokine signaling and leukocyte trafficking that influence the tumor 
microenvironment. Overall, our work supports the negative role of Wnt5A in 
immunomodulation through downregulating inflammatory cytokine and chemokine 
expression and subsequent immune infiltration to the tumor microenvironment. 
Inhibition of Wnt5A could be used in combinatorial approaches with immunotherapy to 
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INTRODUCTION 
Pathology of melanoma 
Melanoma is a type of skin cancer that occurs when melanocytes, the melanin-
producing cells, are mutated and become cancerous. Although invasive melanoma 
accounts for only about 1% of all skin cancers, due to the highly invasive nature of this 
disease, it is responsible for a large majority of skin cancer deaths1,2. Moreover, the 
incidence of melanoma has been rising rapidly over the past few decades. Particularly, 
the number of newly diagnosed invasive melanoma has increased by approximately 
40% between 2009 and 20193. The statistics raise awareness about melanoma as a 
severe public health concern. 
Cutaneous melanoma progresses in a stepwise fashion. Primary melanoma 
develops from an initial radial growth phase (RGP) and may be followed by a vertical 
growth phase (VGP)4,5. Radial growth phase melanoma grows horizontally and radially 
within the epidermis or sometimes invades the dermis4-6. It is characterized by a flat and 
irregular lesion without the formation of a nodule4-6. In the vertical growth phase, the 
lesion grows vertically and deeper into the tissues, forming a tumor4-6. The VGP 
melanoma is invasive and has acquired competence of metastasis4-6.  
To describe the extent of cancer in clinics, growth phases are re-put to be 
sequential stages based on the TNM (tumor, nodes and metastasis) system. The 
staging process serves as an indicator of prognosis and can assist in treatment 
decisions. There are five stages of melanoma, as shown in Figure 1. The earliest stage 
of melanoma is stage 0, where the malignant tumor is in situ and confined to the 
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epidermis, the upper layer of the skin. Subsequently, the tumor invades from the 
epidermis into the dermis, known as stage I and stage II melanoma. Both stages are 
invasive but localized, with stage II melanoma penetrating deeper into the dermis and 
developing ulceration1. Stage III melanoma has spread into the regional lymph nodes or 
tissues and shown evidence of satellite or in-transit metastasis1. Stage IV melanoma is 
known as metastatic melanoma. The malignant tumor has traveled beyond the original 
tumor site and regional lymph nodes to more distant areas of the body, such as lungs, 
liver, brain, bones and intestines1. Melanoma can be treated most effectively in its early 
stages when localized (stage 0, I, and II). As indicated by 2017 AJCC Melanoma 
Staging and Classification, with surgical removal, individuals with Stage 0 melanoma 
have a ten-year overall survival rate of 99%-100%7. On the other hand, the ten-year 
survival rate for Stage IV melanoma patients was about 10% to 15%7.  
 
Therapeutic resistance in melanoma patients  
Clinical breakthroughs of molecular-targeted therapy and immunotherapy have 
improved the prognosis for patients with invasive melanoma. Small molecules such as 
Vemurafenib and Dabrafenib have been designed to specifically inhibit the mutated 
BRAFV600E in the MAPK pathway, which is mutated in more than two-thirds of 
melanoma cases8,9. These BRAF inhibitors (BRAFis) have achieved benefits in both 
tumor burden and overall survival in metastatic melanoma patients10-12. However, the 
duration of response is limited by resistance to BRAFis and subsequent relapse13. 
Although monoclonal antibodies against immune checkpoint inhibitors (ICIs), such as 
anti-PD-1 (Pembrolizumab, Nivolumab) and anti-CTLA4 (Ipilimumab), have 
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demonstrated clinical efficacy and durable responses in treating metastatic melanoma, 
a proportion of 40-60% of patients present acquired resistance and relapse within 2 
years14-17. The resistance to multiple ICIs is largely attributed to the immunosuppressive 
tumor microenvironment and the absence of T cell infiltration, characterized as “cold 
tumors”18. On the other hand, the hot tumor microenvironment is T cell inflamed and 
presents higher response rates to immunotherapy18,19. Therapeutic approaches that 
could turn cold into hot tumors would be necessary to improve the response to 
immunotherapy. Therefore, it emphasizes an urgent need to identify new molecular 
targets and explore mechanisms involved in immunomodulatory pathways to treat 
advanced melanoma.  
 
Wnt5A signaling and its potential role in immunomodulation 
Recent studies have reported that Wnt5A was overexpressed in BRAFi-resistant 
cell lines and patient tumors13. Wnt5A is a member of the Wingless/integrase 1 (WNT) 
family of lipid-modified glycoproteins that are involved in cell growth, motility, adhesion, 
polarity and differentiation during embryonic development20,21. Wnt signals are divided 
into two major categories: the canonical pathway, which relies on the accumulation and 
transcriptional activity of β-catenin, and the non-canonical pathway that is independent 
of β-catenin21,22. Wnt5A is a highly conserved non-canonical Wnt ligand regulating 
planar cell polarity (PCP), convergent extension (CE), and epithelial-mesenchymal 
interaction during embryonic morphogenesis by binding to the Frizzled-, ROR- and Ryk 
family receptors and activating the downstream PCP or Wnt/Ca2+ pathway20,22.  In 
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addition to its critical role in embryogenesis, the upregulation of Wnt5A is emerging as 
an important event in cancer progression. Studies have demonstrated the involvement 
of Wnt5A in regulating a diverse array of tumor cell behaviors, including inflammation, 
migration and metastasis (Figure 2)22. In this work, we focused on the role of Wnt5A in 
tumor microenvironment and inflammation.  
Cancer cells in the tumor microenvironment (TME) release cytokines and 
chemokines to regulate inflammation and dictate the shifting of immune cells to favor 
cancer progression20. Although Wnt5A is reported to regulate the inflammatory process 
in both infectious and inflammatory diseases, its role in either inflammation in the 
context of melanoma or tumor evasion from immune destruction has been poorly 
investigated. In 2021, Douglass et al. suggested that Myeloid-Derived Suppressor Cells 
(MDSCs) act as a major source of Wnt5A and also depend on Wnt5A to create an 
immunosuppressive microenvironment3. Therefore, we decided to expand on this data 
and explore the role of Wnt5A from melanoma cells in the immunomodulation of the 
TME. It is believed that Wnt5A mediates the production of inflammatory cytokines and 
chemokines to reshape the TME23. Given the well-established role of the majority of 
cytokines and chemokines in leukocyte migration during inflammation and immune 
surveillance, it is important to understand how cytokine and chemokine expression are 
influenced by Wnt5A. The identification of these cytokines and chemokines offers not 
only an insight into the immunomodulatory functions of Wnt5A but also a potential 
therapeutic target in treating melanoma.  
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The role of CCL2/CCR2 and CXCL10/CXCR3 signaling in leukocyte trafficking 
Given the role of Wnt5A in regulating the suppressive activity of MDSCs24, we 
queried whether Wnt5A from cancer cells has effects on chemokines involved in 
myeloid cell chemotaxis. CCL2 or monocyte attractant protein-1 (MCP-1) is a member 
of the CC chemokine family and binds to CCR2, a seven-transmembrane G-protein-
coupled receptor. CCL2 signals act as a chemoattractant for myeloid and lymphoid 
cells, including monocytes25, dendritic cells26,27, macrophages27, MDSCs28, T cells29, 
and NK cells30. Since CCL2/CCR2 signaling is critical in myeloid cell infiltration, it is of 
utmost importance to better understand the role of Wnt5A in this process.  
Furthermore, as we discussed before, cold tumors that are limited in T cell 
infiltration exist as a major challenge for immunotherapy. The conversion of a “cold” into 
an inflamed “hot” tumor would require prior therapies to induce tumor T cell infiltration. 
Thus, we wonder whether Wnt5A is involved in the regulation of chemokine signaling 
that is responsible for T cell recruitment. CXCR3 is a seven transmembrane G protein-
coupled receptor predominantly expressed on T lymphocytes31-33. CXCL10, known as 
interferon-γ inducible protein 10, is a pro-inflammatory chemokine that specifically 
activates the CXCR3 receptor. CXCL10/CXCR3 signaling exerts the “homing” function 
to CXCR3+ T cells by attracting them towards inflammatory, infectious and neoplastic 
sites34. Therefore, investigations into the role of CXCL10/CXCR3 signaling in the 
Wnt5A-overexpressed tumor microenvironment would provide a deep understanding of 
tumor T cell infiltration and better treatments of cold tumors. 
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YUMM cell lines 
To study the effect of Wnt5A on chemokine secretions, we utilized is Yale 
University Mouse Melanoma (YUMM) cell lines developed by Dr. Marcus Bosenberg. 
Murine cancer cell lines have been widely used in cancer research. The initial B16 
mouse melanoma cell line was generated from a naturally arising melanocytic tumor in 
an inbred C57Bl/6 mouse35. Although the B16 cell line has been a powerful tool to study 
cancer metastasis, the driver mutations of B16 have not been well-defined and tumor 
immune responses are compromised due to low levels of MHC class I molecules36,37 . 
Therefore, in order to make mouse models more experimentally tractable, 
immunocompetent GEMM (genetically engineered mouse model) with specific human-
relevant oncogenic driver mutations are needed. The YUMM cell lines were established 
from melanocyte specific Braf/Pten mouse models.  
In this project, the cell line we used, YUMM1.7, was derived from mice bearing a 
BRAFV600E mutation and Pten and Cdkn2a inactivation36. The YUMM cell lines are 
generally recognized as poorly immunogenic due to a low number of somatic genetic 
changes38,39. An exception to this is YUMM2.1 cell line. When implanted into mice and 
treated with anti-PD1 therapy, it induces abundant immune cell infiltrates and strong 
anti-tumor responses40. The robust immune response of YUMM2.1 melanoma is 
characterized by high levels of inflammatory and chemotaxis-related genes that are 
important in immune cell infiltration and T cell priming39,41. Therefore, YUMM2.1 cells 
may not be ideal for studying the innate and acquired resistance to immunotherapy. 
YUMM1.7 cells, as demonstrated by Kugel and Weeraratna et al. (2018), are useful to 
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study the age-related responses to PD-1 inhibition and aged-related changes in the 
immune microenvironment. In our study, we continued to use YUMM1.7 to explore the 
impact of Wnt5A on the tumor immune microenvironment.  
Our hypothesis is that Wnt5A can downregulate the expression of pro-
inflammatory chemokines, such as CCL2 and CXCL10, and/or induce the 
overexpression of anti-inflammatory cytokines. The subsequent reduction in the 
recruitment of immune cells to the primary tumor shifts the immune microenvironment to 
favor melanoma progression. The mouse chemokine array and qPCR analysis on 
Wnt5A-overexpressed YUMM1.7 cells provided us with the expression patterns of 
inflammatory cytokines and chemokines. By performing flow cytometry on immune 
populations from the tumor and lymphoid organs, we further examined the immune 
profiles of transgenic mouse models as well as the influence of Wnt5A on chemokine 
signaling and immune infiltration.
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MATERIALS AND METHODS 
Cell Culture 
YUMM1.7 melanoma cell lines were obtained from Dr. Marcus Bosenberg, Yale 
University. YUMM1.7 cells were maintained in GibcoTM DMEM/F-12 medium (Thermo 
Fisher Scientific), supplemented with 10% FCS, 1% penicillin and streptomycin, and 1% 
L-Glutamine. FS4, FS5, FS12 and FS14 melanoma cells were maintained in RPMI 1640 
medium (Invitrogen) supplemented with 10% FCS, and 1% penicillin and streptomycin. 
1205Lu cells and MW164 cells were cultured in a 4: 1 mixture of MCDB 153 medium 
(Sigma) with L-15 medium (Cellgro) supplemented with 2% FBS and 1.6 mM CaCl2. All 
cell lines were cultured at 37°C in 5% CO2 and the medium was replaced as required.  
Lentiviral Transduction and Wnt5A Induction 
The doxycycline-inducible Wnt5A vector: pLV[Exp]-mCherry:T2A:Bsd-
TRE3G>hWNT5A was designed by Dr. Mitchell Fane and was sourced from vector 
builder (Figure 3A). Lentiviral production (Lenti-X 293T) was performed by Dr. Mitchell 
Fane in accordance with the protocol provided by the Broad Institute. YUMM1.7 cells 
were transduced with lentivirus in the presence of 10 μg/ml polybrene (Sigma) for 48 
hours and selected through puromycin and selection markers (mCherry). 1 μg/ml of 
doxycycline was used to induce the overexpression of Wnt5A. 
Reverse Transcription  
RNA from both Dox-induced and No dox-added groups was extracted using 
QIAGEN RNeasy Mini Kit (#74106) according to the manufacturer’s protocol. The 
extracted RNA was quantified via NanoDrop spectrophotometer (Thermo Fisher 
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Scientific). 2 ng of RNA were reverse transcribed using Bio-Rad iScript cDNA Synthesis 
Kit (#1708891) following the manufacturer’s instructions.   
Real-time Quantitative PCR 
Specific primers were customized and obtained from Integrated DNA 
Technologies. The primer sequences have been described in Table 1. qPCR was 
performed with Fast 96-well and SYBRgreen (Thermo Fisher Scientific) on a 
QuantStudio 7 Flex Real-Time PCR System (Thermo Fisher Scientific). Statistical 
analysis was performed using the 2-ΔΔCT method and Student t test.  
Table 1 Primer sequences designed for genes of interest. 
Gene Sense Anti-sense 
Beta-Actin gaggtatcctgaccctgaagta cacacgcagctcattgtaga 
Wnt5A attcttggtggtcgctaggta gcgcttctccgatgtactgc 
CCL2 cactcacctgctgctactca gcttggtgacaaaaactacagc 
CCL5 tttgcctacctctccctcg cgactgcaagattggagcact 
CXCL1 gctgggattcacctcaagaa tggctatgacttcggtttgg 
CXCL9 agagtagggaccacagactatt gcctttctacctctcacacatac 
CXCL10 tcaggctcgtcagttctaagt ccttgggaagatggtggttaag 
CXCL11 aagcaagctcgcctcataat tcctggcacagagttcttattg 
CXCL12 ggagccatagtaatgccagtag ctgacaccggaaagctacaa 
IFNG acagcaaggcgaaaaaggat tgagctcattgaatgcttgg 
TNFA ccaccacgctcttctgtctac agggtctgggccatagaact 
IL-6 gacaaagccagagtccttcagagag ctaggtttgccgagtagatctc 
IL-10 cttactgactggcatgaggatca gcagctctaggagcatgtgg 
 
Proteome Profiler Array 
YUMM1.7 cell lines were plated and lysed with RIPA lysis buffer supplemented 
with proteinase and phosphatase inhibitors. The whole protein extract was quantified via 
a PierceTM BCA protein assay kit (#23225, Thermo Fisher Scientific). The Proteome 
Profiler Mouse Chemokine Array (#ARY020, R&D Systems) was used to analyze the 
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expression profiles of chemokines in 200 μg of cell lysates in accordance with the 
manufacturer’s protocol. The array membranes were exposed to X-ray film for multiple 
exposure times and images were captured by Syngene G:Box. Densitometry analysis 
was performed by Image J.  
Western Blotting 
Total protein lysate was quantified by procedures mentioned above and 50 μg 
was prepared and loaded into precast NuPAGE™ 4-12% Bis-Tris Protein Gels 
(#NP0321BOX, Thermo Fisher Scientific). Gels were run at 160 volts. Samples were 
transferred onto PVDF membrane via the iBlot system (Invitrogen). The membranes 
were then blocked with 5% milk in TBST for 1 hour and incubated with the primary 
antibody diluted in 1% BSA/TBST at 4 °C overnight. The membranes were washed in 
TBST. 0.2 μg/ml of the corresponding HRP conjugated secondary antibody was applied 
to the membranes and incubated at room temperature for 2 hours. Proteins were 
visualized by ECL prime and detected by ImageQuantTM LAS 4000 (GE Healthcare Life 
Sciences). 
Wound healing assay 
YUMM1.7 cells were seeded in a 6-well plate to reach 80% confluency. Cells 
were treated with 1 ng/ml of doxycycline and then starved with DMEM/F12 medium 
overnight. The wound was created by scratching horizontally with a 200 ul sterile pipette 
tip. After scratching, cells were maintained in DMEM/F-12 medium, supplemented with 
10% FCS, 1% L-Glutamine, 1% penicillin and streptomycin. The wounds were 
photographed at the beginning (0h) under the microscope using the 4x objective lens. 
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The dishes were taken out of the incubator to be examined periodically and then 
returned to resume incubation. 
Immunohistochemistry Assay 
Primary YUMM1.7 melanoma tumors were sectioned and embedded in paraffin. 
Tumor sections were deparaffinized using xylene and subsequently rehydrated by a 
series of different concentrations of ethanol. Heat-mediated antigen retrieval was 
conducted by treating sections with antigen retrieval buffer (#H-3300, Vector 
Laboratory) for 20 minutes. Tumor sections were blocked with hydrogen peroxide 
blocking reagent (#ab64218, Abcam) for 15 minutes, which was followed by protein 
block (#ab64226, Abcam) for 30 minutes. Antibodies of interest (Wnt5A, #mab645, R&D 
systems) were prepared with antibody diluent (#S0809, Dako) and applied to slides and 
incubated at 4°C overnight in a humidified chamber. Samples were washed with PBS 
and incubated with biotinylated goat anti-rabbit secondary antibody (#ab64256, Abcam) 
for 1 hour. Samples were washed with PBS and treated with Streptavidin-HRP for 30 
minutes. Samples were washed with PBS and incubated with AEC (3-amino-9-ethyl-1-
carbazole) chromogen (#1T0080T, Enquire Bioreagents) for a certain amount of time 
and counterstained with Mayer’s hematoxylin (Millipore Sigma) for 10 seconds. The 
samples were rinsed with PBS and mounted in Aquamount (#H-5501-60, Vector 
Laboratory). 
Tissue processing and Flow Cytometry  
Flow cytometry was carried out using a Northern Lights Flow Cytometer (Cytek 
Biosciences). Prior experiments with tumors were performed by Dr. Stephen Douglass 
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and analyzed by me under his guidance. Isolation of leukocytes from spleens and bone 
marrow was performed in assistance with Dr. Stephen Douglass. Tumors no larger than 
1500 mm3 were isolated and chopped into small fragments and incubated in the Tumor 
Dissociation Kit, mouse (#130-096-730, Miltenyi Biotec) at 37 °C for 1 hour. Isolated 
tumors and spleens were mashed through a 4 μm cell strainer. Bone marrow was 
harvested by stripping the leg of skin and muscle and isolating the femur of mice and 
flushing out bone marrow from the center of the bone using a 25G needle. Harvested 
tumor and spleen cells bone marrows were centrifuged to remove the supernatant and 
resuspended with ammonium chloride (ACK) RBC lysis buffer for 1 minute. 4 ml of 
FACS buffer (PBS with 1% FCS and 5mM EDTA) were added and centrifuged to 
discard the supernatant. The resulting cell pellet was resuspended and cells were 
rinsed and stained with antibodies in MACS buffer (0.5% FCS and 2.5mM EDTA in 
PBS) for 1 hour at 37°C in the dark. The antibodies used are listed in Table 2, Table 3 
and Table 4.  
Cell surface staining:  
Antibody combinations mentioned in Tables 2 and 3 were in 1:200 dilutions. 
Single staining (for each fluorochrome) was used as a reference control. After staining, 
cells were washed with 1ml of FACS buffer and resuspended in 500μl of PBS.  
Intracellular staining (Foxp3): 
Following the completion of cell surface staining, cells were pelleted by 
centrifuging at 400 xG for 5mins. The pellet was resuspended in 1ml of prepared 
Fix/Perm buffer (x4, Biolegend) and left for 1hour at room temperature in the dark. 1ml 
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of Perm Buffer (x10) was added on top of the suspension and centrifuged at 400 xG for 
5mins. The cell pellet was resuspended and incubated with 200 μl of Foxp3 antibody 
(listed in Table 4) diluted 1:200 in perm buffer for 1 hour in the dark. After staining, cells 
were washed with 2 ml of perm buffer and resuspended in 500 μl of PBS.  
FACS analysis was performed using FlowJo software.  
Statistical Analysis 
All the data were repeated in duplicate at least. Data are presented as mean ± 
standard error of the mean (SEM) unless otherwise stated. Statistical analysis was 
performed with GraphPad Prism software. Comparison between groups was conducted 
using Student two-tailed t-test to determine p values. P-value <0.05 was considered 
significant (*p < 0.05; **p < 0.01; ***p < 0.001; N.S., not significant).  
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Table 2 Antibodies and fluorochromes used to stain myeloid cell population. 
Myeloid Cell Populations 
Company Catalog # Target Fluorochrome Clone 
BioLegend 103112 CD45 PerCP-Cy5.5 30-f11 
Invitrogen 25-0112-81 CD11b Bv510 M1/70 
BioLegend 123117 F4/80 APC-Cy7 BM8 
BD Bioscience 553104 Ly6C AF700 AL-21 
BD Bioscience 561104 Ly6G Pe-Cy7 1A8 
BioLegend 117339 CD11c Bv650 N418 
BioLegend 114406 MHCII FITC 25-9-19 
BioLegend 120119 CCR7 Bv421 4B12 
BioLegend 150621 CCR2 Bv785 SA203G11 
BioLegend 105007 CD86 PE GL-1 
 
Table 3 Antibodies and fluorochromes used to stain Lymphocytes. 
Lymphocyte Populations 
Company Catalog # Target Fluorochrome Clone 
BioLegend 103112 CD45 PerCP-Cy5.5 30-f11 
BioLegend 100553 CD4 FITC RM4-5 
BioLegend 126609 CD8 PE YTS156.7.7 
BioLegend 137627 Nkp46 AF647 29A1.4 
BioLegend 101915 CD25 Pe-Cy7 3C7 
BioLegend 104453 CD62L Bv650 MEL-14 
BioLegend 109109 PD-1 APC-Cy7 RMP1-30 
BioLegend 120119 CCR7 Bv421 4B12 
BioLegend 150621 CCR2 Bv785 SA203G11 
BioLegend 126527 CXCR3 Bv510 CXCR3-173 
 
Table 4 Antibodies and fluorochromes used to stain Tregs. 
Regulatory T cells 
BioLegend 103112 CD45 PerCP-Cy5.5 30-f11 
BioLegend 100553 CD4 FITC RM4-5 
BioLegend 126410 Foxp3 AF647 MF-14 
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RESULTS 
Induction of Wnt5A expression in YUMM1.7 cells 
YUMM1.7 melanoma cells transduced with plasmid vectors were examined for 
Wnt5A expression using both western blotting and qPCR. The cells treated with 
doxycycline were referred to as the dox-treated group, and otherwise, it was named the 
no dox-treated group. In the absence of doxycycline, the expression of Wnt5A by 
YUMM1.7 cells was comparable to the previously characterized Wnt5A-low human 
melanoma cell lines (FS12, FS14 and WM164) (Figure 3C). After the treatment of 
doxycycline, Wnt5A expression was dramatically increased in YUMM1.7 cells (Figure 
3C). It was quantified to be approximately 50 times more than the previously 
characterized Wnt5A-high melanoma cell lines (FS4, FS5 and 1205Lu). As indicated by 
Figure 3B, Wnt5A transcripts also showed more than an 80-fold increase in the dox-
treated group. To further visualize Wnt5A expression patterns in vivo, dox-induced 
YUMM1.7 cells were injected sub-dermally into C57Bl/6 mice. Tumor sections in the 
dox-treated group showed high levels of Wnt5A compared to the no dox-treated group 
(Figure 3D). Interestingly, the no dox-treated group also expressed certain amounts of 
Wnt5A due to the endogenous expression in melanoma cells. 
 
Melanoma-derived Wnt5A downregulates the expressions of inflammatory 
cytokines and chemokines: CXCL10, CCL2, IFN-γ and TNF-α 
Since Wnt5A has been implicated as a regulator of inflammation, we wanted to 
assess whether Wnt5A can modulate the expression of chemokines by melanoma cells. 
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Protein extracts from the dox-treated and no dox-treated group were evaluated using a 
mouse chemokine array (Figure 4B). This analysis showed that Wnt5A downregulated 
the expression of several chemokines, including CXCL10, CCL2, CXCL1 and CCL5 
(Figure 4A). To validate the effect of Wnt5A on chemokine reduction, we performed 
real-time qPCR analysis on several cytokine/chemokine transcripts. The levels of 
CXCL10 and CCL2 transcripts significantly decreased with the overexpression of 
Wnt5A (Figure 4C). Of note, CXCL9 and CXCL11, which share the same chemokine 
receptor CXCR3 with CXCL10, did not show a reduction in the transcription level in the 
dox-treated group (Figure 5A). Moreover, Wnt5A did not downregulate CXCL1 and 
CCL5 at the transcription level (Figure 5A), ruling out their participation in immune 
regulation in YUMM1.7 cells.  
Previous studies have shown that the upregulated Wnt5A can induce the 
expression of IL-6 in immune and non-immune cells42. Besides promoting pro-
inflammatory cytokine secretion, Wnt5A stimulates the secretion of anti-inflammatory 
cytokine IL-10 in immune cells through Wnt5a/TLR/MyD88 pathway43. Furthermore, 
TNF-α and IFN-γ play controversial roles in melanoma. In addition to anti-tumor effects, 
they have been demonstrated to enhance the expression of PD-L1 in melanoma, 
leading to adaptive immune resistance and melanoma relapse44-46. Therefore, we were 
interested to see whether the increased Wnt5A signaling can modulate the release of 
pro-inflammatory cytokines (IFN-γ, TNF-α and IL-6) and anti-inflammatory cytokines (IL-
10) in our case to trigger immunosuppression. As shown in Figure 5B, there were no 
significant changes in the transcription levels of IL-6 and IL-10 in the dox-treated group. 
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Therefore, Wnt5A is not associated with the regulation of these two cytokines in 
YUMM1.7 cells. Of note, the expressions of IFNG and TNFA were decreased with the 
overexpression of Wnt5A and differed significantly from the no dox-treated group 
(Figure 5B). If TNF-α and IFN-γ are directly involved in tumor promotion and immune 
resistance in YUMM1.7 melanoma, the expression levels should be increased. The 
downregulated expressions we observed instead cannot support the assumption of their 
direct contribution to immunosuppression. Interestingly, previous studies suggested the 
involvement of IFN-γ and TNF-α in macrophage polarization. The polarization to M1 or 
M2 macrophages and their migrations to the tumor microenvironment could be another 
important aspect to study the immunosuppression. The possible impact of IFN-γ and 
TNF-α on macrophage polarization and recruitment will be discussed later. 
 
Enhanced invasive ability of Wnt5A-overexpressed YUMM1.7 cells 
Weeraratna et al. have previously demonstrated that Wnt5A signaling can 
increase the invasive ability of melanoma cells2. To understand the impact of the 
downregulated cytokines and chemokines on YUMM1.7 cells, we tested cell motility in 
vitro. In the wound healing assay, we examined cell migration in response to the scratch 
wound in the absence or presence of doxycycline treatment. Images of scratch areas 
from the time points 0, 3, 5, 7, 9, 11 hours are illustrated in Figure 5C. When treated 
with doxycycline, the scratch was closed within 11 hours, whereas the no dox-treated 
group did not show apparent signs of the scratch closure. Therefore, the decreased 
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cytokine and chemokine signaling in the Wnt5A-overexpressed YUMM1.7 cells may 
correlate with the enhanced invasion.  
 
Flow cytometric analysis of macrophages and dendritic cells from the tumor and 
spleen 
To further visualize the effect of Wnt5A and chemokine signaling on the immune 
infiltration, YUMM1.7 cells were implanted into C57Bl/6 mice and treated with either 200 
ng/ml rWnt5A (recombinant Wnt5A) or PBS every 3 to 4 days by Dr. Stephen Douglass. 
The tumor and spleen were isolated and single cells were analyzed by flow cytometry. 
Since CCL2 is a potent chemoattractant protein for monocytes25,47, we were specifically 
interested in the infiltration patterns of these cells. Monocytes have a wide range of 
plasticity and depend on the TME to differentiate to macrophages and dendritic cells. 
There were significant decreases in the levels of macrophages and dendritic cells in the 
tumor with the stimulation of rWnt5A (Figure 6), which were not observed in the spleen, 
suggesting the Wnt5A-related reduction is tumor-specific. On the contrary, animals 
treated with rWnt5A had significantly increased the frequencies of macrophages and 
dendritic cells in the spleen (Figures 6A&B), probably due to the increased amounts of 
tumor antigen. Overall, Wnt5A can reduce the tumor-specific infiltration of macrophages 
and dendritic cells and potentially create an immunosuppressive microenvironment for 
cancer metastasis.  
The receptor CXCR3, as introduced before, is predominantly expressed on T 
lymphocytes31. Its ligand, CXCL10, was demonstrated to be downregulated by cancer-
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derived Wnt5A in our experiments. Therefore, we wondered whether the decreased 
CXCL10 expression would influence T cell recruitment. Interestingly, no significant 
changes in the infiltration of tumor CD4+ and CD8+ T cells were observed in the rWnt5A-
treated group (Figures 6E&F). There were also no differences in the frequencies of 
spleen T cells with the stimulation of rWnt5A (Figures 6E&F). Overall, the decreased 
level of CXCL10 in the tumor microenvironment exerts a very limited impact on T cell 
recruitment.  
 
Immunophenotyping of myeloid cell populations in murine bone marrow and 
spleen 
Recent breakthroughs in tumor immunotherapy have been driven by a deeper 
understanding of immunoregulatory processes in the tumor microenvironment. We 
believe that continued analysis of basic details of the immunologic features in mouse 
models enables the improvement of current immunotherapeutic strategies and the 
identification of potential molecular targets. As discussed before, CCL2/CCR2 signaling 
acts as an important player in monocyte recruitment and CXCL10/CXCR3 signaling is 
predominantly involved in attracting T lymphocytes. Wnt5A downregulated CCL2 and 
CXCL10 at both the transcription and protein levels (Figure 4). Therefore, we wondered 
whether the overexpression of Wnt5A would influence the expressions of CCR2 and 
CXCR3 on immune populations and regulate their migrations into the tumor. 
To characterize the murine immune cell populations, Dr. Stephen Douglass and I 
performed flow cytometry on leukocytes isolated from bone marrow and spleen. The 
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gating strategy developed by Dr. Stephen Douglass and myself is shown in Figure 7. 
After the debris was eliminated by FSC-A vs. SSC-A (data not shown) and single cells 
were selected by FSC-H vs. FSC-A gating (data not shown), immune cells were 
identified by the expression of CD45, previously known as CLA (common leukocyte 
antigen) (Figures 7&8). The percentages of immune cells in the bone marrow and 
spleen were comparable (Figures 7&8). Myeloid cells were then identified based on the 
surface marker CD11b. Myeloid cells accounted for the majority of immune cells in the 
bone marrow (87.7%) and spleen (75.3%) (Figures 7&8).  
Within the myeloid compartment, Ly6C and F4/80 were used to define 
macrophages. Dendritic cells were identified based on the expression of surface 
CD11c. Neutrophils were distinguished by myeloid cell marker CD11b, then F4/80 
negative populations were selected to rule out macrophages and then the neutrophil-
specific marker Ly6G was used. As potent antigen-presenting cells (APCs), the 
activated neutrophils often differ from resting neutrophils based on the upregulation of 
MHC class II48. Therefore, the activated neutrophil populations were characterized by 
high levels of MHC class II. MDSCs were identified by the expression of myeloid cell 
marker CD11b and the lack of surface marker F4/80. Also, MDSCs were generally 
recognized as MHC class II negative49. Two populations of MDSCs, M-MDSCs and 
PMN-MDSCs, were distinguished by the proportion of the expression of surface 
markers: Ly6C and Ly6G. As shown in Figures 7&8, MDSCs towards the monocytic 
lineages (M-MDSCs) are Ly6ChiLy6G-, while polymorphonuclear MDSCs (PMN-
MDSCs) are Ly6CloLy6G+.  
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The observed frequencies of macrophages, dendritic cells and two populations of 
MDSCs in BM and spleen were similar (Figures 7&8). Notably, there were very few 
percentages of M-MDSCs in both bone marrow (2.92%) and spleen (1.51%). 
Considering that MDSCs accumulate in the tumor or chronically inflamed site to 
suppress immune cell effector functions, it is reasonable to observe low numbers of M-
MDSCs in mice without pathology and tumor. Further experiments would be conducted 
on YUMM1.7 melanoma-bearing mice to examine the tumor-specific infiltration of M-
MDSCs. Moreover, although bone marrow harbors substantial populations of immune 
cells, it accommodated a lower percentage of the activated neutrophils (11.5%) than the 
spleen (88.9%) (Figures 7&8). It suggests that there are considerable amounts of 
immature myeloid progenitors in the bone marrow. The acquisition of antigen-presenting 
functions in neutrophils and other antigen-presenting cells mainly happens in the spleen 
rather than the bone marrow.  
Further characterization of macrophage and dendritic cell subsets was based on 
the activation marker CD86 and chemokine receptor CCR7. Macrophages are 
phagocytic cells that play an important role in innate immunity and activating adaptive 
immunity. There are two categories of macrophages: M1 and M2. M1 macrophages are 
classically activated and secrete pro-inflammatory cytokines to initiate host defense and 
anti-tumor properties50. Polarized M2 macrophages produce anti-inflammatory cytokines 
alternatively, which suppress the inflammatory response, therefore inhibiting tumor 
immunity and enhancing angiogenesis and ECM remodeling50. M1 macrophages were 
distinguished from M2 by high expression of MHC class II and CD86. CD86 is a co-
 22 
stimulatory molecule expressed on antigen-presenting cells (APC) such as 
macrophages and dendritic cells, which is required for T cell activation. Dendritic cells 
express minimal amounts of CD86 in the absence of antigen but upregulate the CD86 
levels during antigen presentation51,52. As shown in Figure 7, bone marrow served as a 
reservoir for both M1 and M2 macrophages though M1 is dominant (69.3%). Spleen 
macrophages were mainly polarized into M1 state as there were 97.9% of M1 
populations (Figure 8). As for dendritic cells, there was only 25.1% expressing high 
levels of MHC class II and CD86 in the bone marrow. The majority of spleen dendritic 
cells (94.5%) were activated and maturated upon the stimulation of antigen, which is 
reasonable due to the nature of spleen as an antigen-presenting site.  
The interaction between chemokine receptor CCR7 and its ligands CCL9/CCL21 
plays a critical role in regulating the specific chemotaxis of M1 macrophages to the 
injured or inflammatory tissue53. Additionally, CCR7 signaling is essential for the 
migration of dendritic cells from the affected tissue to lymphoid organs, which allows for 
the antigen presentation to cognate T cells and the activation of adaptive immunity25,54. 
In the spleen, a higher frequency (64.6%) of M1 macrophages with the expressions of 
MHC class II and CCR7 was observed compared to the bone marrow (13.5%). It is 
possible that significant amounts of M2 macrophages were derived from precursor cells 
in the bone marrow, which reduces the proportion of M1 populations. The frequencies of 
dendritic cells expressing both MHC class II and CCR7 in the bone marrow and spleen 
were comparable (Figures 7&8).  
 23 
Immunophenotyping of lymphocyte populations in murine bone marrow and 
spleen 
Different subsets of T lymphocytes in bone marrow, spleen, and blood were also 
characterized by flow cytometric analysis. CD4+ and CD8+ T lymphocytes were 
identified by their surface markers: CD4 and CD8, respectively. Markers consistent with 
T cell activation such as CD25 and PD-1 and the marker that distinguishes central 
memory T cells, CD62L, were used to characterize T cell subsets in the bone marrow 
and spleen. CD25 is the alpha chain of the interleukin-2 (IL-2) receptor. IL-2/CD25 
signaling is required for T cell development and antigen-specific T cell responses55. 
Upon activation by T cell receptor (TCR) and co-stimulatory molecules, T cells 
upregulate the expression of CD25 and become highly IL-2 sensitive56. CD25 
expression level further controls T cell lineage differentiation57. Naïve T cells were 
identified based on the surface expression of CD62L and the absence of CD25. The 
CD62L+ CD25+ subset includes the activated central memory T cells (Tcm cells) and the 
CD62L- CD25+ subset includes the activated effector memory T cells (Tem cells). The 
CD62L- CD25- subset is recognized as resting Tems.  
As shown in Figures 9A&B, the frequencies of CD4+ and CD8+ T cells in the 
spleen were 17.6% and 10.9%, respectively. Bone marrow was less abundant in both 
CD4+ (3.42%) and CD8+ (3.36%) T cells, which is reasonable as bone marrow is not the 
site for differentiated T cells. CD4+ T cells in the bone marrow, though in a few amounts, 
showed a certain distribution pattern of subpopulations. CD4+ T cells mainly existed as 
Tem cells, being either resting (41.1%) or the activated (46.8%). On the other hand, the 
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activated CD4+ Tem cells only accounted for 9.54% in the spleen. The majority of 
spleen CD4+ T cells were naïve or resting Tem. Interestingly, most CD8+ T cells in the 
spleen (86.4%) and bone marrow (60.3%) existed as naïve T cells, and the remaining 
were resting Tem cells. Finally, the expressions of CD62L and immune checkpoint 
protein PD-1 in all CD4+ and CD8+ T cells in the bone marrow and spleen followed the 
similar expression patterns as CD25 in conjugation with CD62L in T cells. 
In addition to CD4+ and CD8+ T cells, regulatory T cell marker Foxp3 was used to 
identify Tregs in the blood and the spleen. The frequencies of Tregs in the blood and 
spleen were similar, which were 3.49% and 4.67%, respectively (Figure 10). Natural 
Killer cells (NK cells) were characterized by the surface maker NKp46. The frequencies 
of NK cells were 2.46% in the bone marrow and 1.45% in the spleen, and no difference 
was observed between the bone marrow and spleen (Figures 9A&B).  
Overall, our flow cytometric analysis on cellular components in the bone marrow 
and spleen validated the optimization of our panel design to identify immune phenotype. 
The accurate location of those cells would be beneficial for our future work on immune 
cell infiltration.  
 
The expressions of chemokine receptors on the identified immune cells 
As indicated previously, CCL2 and CXCL10 were shown to be decreased with 
the overexpression of Wnt5A in YUMM 1.7 cells. To study the effect of Wnt5A on the 
migrations of CCR2+ and CXCR3+ immune populations, the expressions of CCR2 and 
CXCR3 on the identified leukocytes were examined. As shown in Figures 11A&C, 
under normal circumstances, CCR2 was mainly expressed on macrophages and 
 25 
dendritic cells, with 43.2% of CCR2+ macrophages residing in the spleen and 45.4% of 
CCR2+ dendritic cells residing in the bone marrow. M-MDSCs, rather than PMN-
MDSCs, also expressed significant amounts of CCR2 on the surface, suggesting CCR2 
could be associated with monocytic lineages. For lymphocytes, a high proportion of NK 
cells in the bone marrow (24.4%) and spleen (22.4%) expressed CCR2, which was not 
observed in CD4+ or CD8+ T cells. Nevertheless, further investigations are needed to 
understand whether NK cells in the tumor microenvironment migrate in a CCR2-
dependent fashion. CXCR3 was expressed on both CD4+ and CD8+ T cells in the bone 
marrow and spleen (Figures 11B&D). Of note, almost all CD8 T cells were CXCR3 
positive, while only a subset of CD4 T cells (58.6% in the BM and 43.3% in the spleen) 
expressed CXCR3. 
Furthermore, the expression patterns of CCR2 and CXCR3 in T cells were 
studied in conjugation with CD62L. The populations of CD62L+CD4+ and CD62L+CD8+ T 
cells were generally CCR2 negative and did not differ significantly between the bone 
marrow and spleen (Figure 9). Although negative for CD62L, CXCR3+CD4+ T cells 
accounted for a significant amount of all CD4+ T cells in the bone marrow (44.4%) and 
spleen (22.9%). Interestingly, 73.5% of CD8+ T cells in the spleen expressed high levels 
of CD62L and CXCR3. For CD8+ T cells in the bone marrow, while less abundant, the 
CD62L+CXCR3+ CD8+ population still accounted for 16.9% (Figure 9). Considering that 
T cells are selected and maturated in the thymus, it is plausible for the difference 
observed between the BM and spleen.  
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Overall, CCR2+ granulocytes are mainly macrophages, dendritic cells and M-
MDSCs in the bone marrow and spleen. T lymphocytes, except for NK cells, do not 
typically express CCR2 on the surface. There is a certain amount of non-central 
memory CD4+ and CD8+ T cells expressing CXCR3 in both the bone marrow and 
spleen. Finally, almost all CD8+ T cells are CXCR3 positive, with a large majority of 
CXCR3+CD8+ central memory T cells enriched in the spleen.
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DISCUSSION 
Wnt5A signaling has long been implicated as a critical player in melanoma 
progression. Recent studies suggested that the overexpression of Wnt5A in metastatic 
melanoma correlates with therapeutic resistance and tumor relapse13,20,23. Poorly 
immunogenic tumors are well known to be negatively associated with the success of 
immunotherapy. In this study, we have found that cancer-derived Wnt5A specifically 
reduces chemokines: CCL2 and CXCL10 secretion from YUMM1.7 melanoma cells in 
vitro. Inflammatory cytokines IFN-γ and TNF-α, which play a controversial role in cancer 
progression, were also downregulated by Wnt5A. Although Wnt5A-overexpressed 
YUMM1.7 cells also exhibited the enhanced invasive ability based on the deficiency in 
the selected cytokines and chemokines. We further demonstrated that the tumor-
specific infiltration of macrophages and dendritic cells is significantly impeded with the 
stimulation of rWnt5A. Combined with previous findings on the regulation of MDSCs by 
Wnt5A in the melanoma microenvironment24, our work highlights the negative role of 
Wnt5A in immunomodulation. Finally, our immune profiling analysis provided an 
optimized method of thoroughly investigating the impact of cancer-derived Wnt5A on 
the infiltration of leukocytes that influence the TME. 
 
CCL2/CCR2 signaling and Tumor-specific infiltration of Monocytic lineages 
As we discussed before, CCL2 level was significantly reduced by Wnt5A in 
YUMM1.7 cells and its receptor, CCR2, was predominantly expressed on macrophages, 
dendritic cells and M-MDSCs (Figure 11). Out of all chemokines we tested, CCL2 is the 
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only monocyte attractant protein that is specifically downregulated by Wnt5A. 
Additionally, based on the evidence of the tumor-specific reductions in macrophage and 
dendritic cell infiltration (Figures 6A&B), we are convinced that melanoma-derived 
Wnt5A regulates the recruitment of macrophages and dendritic cells to the tumor 
microenvironment through CCL2/CCR2 signaling. In the future, we aim to build a direct 
connection between CCL2/CCR2 signaling and the recruitment of macrophages and 
dendritic cells to the primary tumor by specifically targeting CCL2/CCR2 signaling. 
Moreover, since CCR2 was also shown to be expressed on NK cells (Figure 11), it 
might be interesting to investigate the infiltration pattern of NK cells in our future study.  
In addition to protective roles in cancer, high levels of CCL2 can correlate with 
adverse prognosis in many cancer patients58-60. CCL2/CCR2 signaling has been 
consistently found to regulate the recruitment of tumor-associated macrophages (M2) 
and MDSCs59. Under normal circumstance, no amount of M2 macrophage was detected 
in the spleen (Figure 8). Future experiments are required to monitor the infiltration of 
M2 macrophages to the tumor microenvironment. MDSCs are potent 
immunosuppressive cells and negatively correlate with immunotherapy success in 
melanoma61,62. A recent study indicates that Wnt5A creates an immunosuppressive 
microenvironment by increasing tumor-specific infiltration of MDSCs24.  Although a 
certain proportion of M-MDSCs expressed CCR2 on their surface (Figure 11), due to 
the decreased level of CCL2 ligands as we observed in YUMM cells, site-specific 
migration of M-MDSCs may not be associated with CCL2/CCR2 signaling. Further 
 29 
studies on mechanisms behind the Wnt5A-mediated regulation of MDSC are required to 
fully address the problem. 
 
CXCL10/CXCR3 signaling and lymphocyte recruitment  
CXCL10/CXCR3 signaling plays a critical role in attracting immune populations, 
especially T lymphocytes, into the inflamed sites34.  Although Wnt5A decreases 
CXCL10 at both the transcriptional and protein levels, no significant changes were 
observed in lymphocyte infiltration (Figures 6E&F).  It is important to note that CXC10 
shares the same receptor with CXCL9 and CXCL11, creating redundancy (with CXCL9) 
in CXCR3 signaling63. Since the expressions of CXCL9 and CXCL11 were not 
specifically regulated by Wnt5A (Figure 5), it is reasonable for no effect observed in T 
cell frequency in the tumor microenvironment with the stimulation of rWnt5A. 
Furthermore, a previous study shows that in the absence of CXCL10, the frequency of 
IFN-γ-producing CD8 T lymphocytes is still elevated in a CXCL9-dependent manner64. 
Therefore, due to complex interactions between CXCR3 and its ligands, it is difficult to 
study the effect on immune infiltration based on a single reduction of CXCL10.  
Moreover, the observation of no significant changes in tumor T cells upon the 
stimulation of rWnt5A (Figures 6E&F) leads us to two assumptions. First of all, Wnt5A 
may not be involved in regulating T cell migration in YUMM1.7 cells. Secondly, 
YUMM1.7-induced melanoma is poorly immunogenic and may lack tumor-specific T cell 
infiltration due to the endogenous Wnt5A. Thus, the treatment of rWnt5A did not further 
reduce the recruitment of T cells. Either way, the comparison of T cell frequencies 
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between healthy and tumor-bearing mice is required. Since CXCL10 is not an ideal 
target to study T cell migration, its receptor, CXCR3, can be investigated instead. As 
shown before, CXCR3 is expressed on a subset of CD4+ T cells and a large majority of 
memory CD8+ T cells (Figure 11). We are interested to see whether the frequencies of 
these CXCR3+ T cells will be changed within the tumor microenvironment created by 
YUMM1.7-induced melanoma. If the infiltration of CXCR3+ T cells is impaired in the 
tumor-bearing group, we wonder whether enhancing CXCR3 signaling would restore 
tumor T cells and turn the cold into a hot tumor.  
 
The expression of CXCR3 and CCR2 on tumor cells 
In addition to the role in recruiting immune cells to restrain melanoma, the 
expression of CXCR3 on melanoma cells has been shown to promote cancer 
metastasis65.  Similarly, CCL2 is demonstrated to promote cancer migration by 
interacting with CCR2 expressed on tumor cells66,67. These studies inspired us to 
investigate the expressions of CXCR3 and CCR2 on YUMM1.7 cells with the 
overexpression of Wnt5A. If the levels of CXCR3 and CCR2 are upregulated by Wnt5A, 
we will further investigate whether these two chemokine receptors would help direct the 
migration of tumor cells to specific anatomic sites to form metastases. Taken together, a 
combination of a blockade of chemokine receptors (such as CXCR3 and CCR2) on 
tumor cells and enhanced chemokine signaling in immune cells may be necessary for 
tumor regression.  
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The role of inflammatory cytokines IFN-γ and TNF-α in immunomodulation 
The secretion of Inflammatory cytokines IFN-γ and TNF-α is associated with 
potent anti-tumor effects. The direct impact of TNF-α on immune activation is possibly 
due to the release of “danger signals” and increases antigen delivery68.  IFN-γ plays a 
critical role in both innate and adaptive immunity by synthesizing granzyme B and 
perforin to initiate apoptosis and upregulating molecules in antigen-presenting 
machinery: MHC class I and class II69,70. IFN-γ also directly regulates the differentiation, 
activation and development of T lymphocytes71. Recent studies add additional sights 
into the roles of IFN-γ and TNF-α in melanoma, pointing out their contribution to the 
upregulation of PD-L145,46. Therefore, we wondered whether the immune escape of 
metastatic melanoma was mediated by IFN-γ and TNF-α. In our results, however, 
Wnt5A significantly downregulates the expression of IFN-γ and TNF-α, ruling out their 
direct contribution to the PD-L1-meditated immunosuppression. Therefore, the anti-
tumor effects of IFN-γ and TNF-α outweigh the pro-tumorigenic effects in the Wnt5A-
overexpressed YUMM cells. We believe that systemic administration or intra-tumoral 
injection of IFN-γ and TNF-α can restore the anti-tumor immunity against melanoma 
cells.  
In addition to the direct anti-tumor effects of IFN-γ and TNF-α, these two 
cytokines also have a role in macrophage polarization. Classically activated 
macrophages (M1) can be induced by IFN-γ alone or combined with LPS or TNF-α, 
while M2 macrophages was typically regulated by IL-472. Therefore, the decreased 
levels of IFN-γ and TNF-α might influence M1 polarization. Based on the impaired 
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tumor infiltration of macrophages due to Wnt5A and decreased level of CCL2 (Figures 
6A&C), it would greatly impact first-line defense, antigen presentation and T cell 
activation when M1 polarization is compromised. Moreover, when monocytic lineages 
are recruited to the tumor, the decreased levels of IFN-γ and TNF-α could lead to an 
imbalance between M1 and M2 macrophages or an increased level of M2 populations, 
which would be associated with immunosuppression and tumor progression.  
Moreover, IFN-γ is the major driver of the CXCR3 signaling that is associated 
with the infiltration of the activated T lymphocytes in melanoma59. CXCL10 is also 
inducible by both IFN-γ and TNF-α59. Therefore, increasing the levels of IFN-γ and 
TNF-α in TME can modulate levels of tumor CXCL10 and other CXCR3 ligands, which 
would further increase intra-tumoral T cell infiltration.  
 
Effects of Matrix Metalloproteinase on chemokines to modulate immune 
responses 
Proteolytic processing of chemokines is a complex process that influences 
chemotactic activities. Matrix Metalloproteinases (MMPs) have been traditionally 
associated with the degradation of extracellular matrix (ECM) components, which are 
important for tumorigenesis, including tumor growth, invasion and metastasis73,74. 
Interestingly, MMPs have been shown to modulate inflammatory and immune 
responses by processing chemokines75. Previous studies demonstrated that MMP-2 
and MMP-9 can cleave CCL2 and CXCL10 in vitro75. The inactivation of CCL2 activity 
leads to two-fold reduction in monocytic cells migration75. In addition, MMP-2 is required 
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for melanoma invasion and Wnt5A treatment has been shown to increase the levels of 
MMP-2 in melanoma cells76. Therefore, we are interested to know whether Wnt5A can 
upregulate MMPs, such as MMP-2 and MMP-9, to cleave CCL2 and CXCL10, which 
would reduce the CCR2+ and CXCR3+ immune populations in the tumor 
microenvironment.  
 
Combination of Wnt5A inhibition with immune checkpoint blockers 
Our observation that links Wnt5A with CCL2 reduction and impaired infiltration of 
macrophages and dendritic cells suggested the key role of Wnt5A in 
immunosuppression. The immunosuppressive tumor microenvironment precludes the 
effect of anti-PD-1 and anti-CTLA-4 therapy. Inhibition of Wnt5A itself or the 
downstream signals could be an effective way to induce immune responses to suppress 
the malignant tumor. Holtzhausen et al. showed that inhibition of Wnt signaling 
synergistically enhances the antitumor effect of anti–CTLA-4 antibody therapy to 
activate T cells in B16 melanoma77, suggesting great potentiality of Wnt5A as in 
combinatorial approaches. In this regard, targeting Wnt5A might turn cold tumors into 
hot tumors. Therefore, combining Wnt5A inhibition with ICIs can be envisioned as a new 
therapy to treat metastatic melanoma. More importantly, molecules that can be used to 
efficiently target Wnt5A signaling pathway are required to be identified.  
 
In summary, our experiments demonstrate that cancer-derived Wnt5A reduces 
the expressions of chemokines CXCL10 and CCL2 and inflammatory cytokines IFN-γ 
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and TNF-α in YUMM1.7 cells, exerting an immunomodulatory role in melanoma. The 
downregulated CCL2/CCR2 signaling impairs tumor-specific infiltration of macrophages 
and dendritic cells, further establishing Wnt5A as a promising therapeutic target for 
melanoma. Combining Wnt5A inhibition with immune checkpoint inhibitors would disrupt 
the immunosuppressive effects and increase the efficacy of immunotherapy. The gating 
strategy we designed allows us to accurately locate immune cells and is beneficial for 
our future work on exploring the role of cancer-derived Wnt5A in melanoma 
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Figure 1 Five Stages of Melanoma. 
Stage 0 melanoma is confined to the epidermis. Stage I and stage II melanoma are still 
localized, but there are cancer cells in both the epidermis and dermis. In stage III 
melanoma, regional lymph nodes are involved in the spread of cancer cells. Stage IV 
melanoma has traveled to distant sites. Reprinted from AIM at Melanoma, Retrieved 





Figure 2 The role of aberrant Wnt5A signaling in cancer progression. 
The overexpression of Wnt5A is associated with cancer proliferation, cellular 
senescence, inflammation, metastasis, metabolism regulation, etc. Adapted from Wnt5a 
Signaling in Cancer, by M. S. Asem, S. Buechler, R. B. Wates, D. L. Miller, & M. S. 




Figure 3 The overexpression of Wnt5A in YUMM1.7 melanoma cells. 
(A) Demonstration of vector design for doxycycline-inducible Wnt5A expression. (B) RT-
PCR analysis show the increased levels of Wnt5A transcripts in YUMM1.7 cells after 
doxycycline induction. (C) The expression levels of Wnt5A in YUMM1.7 melanoma cells 
before and after Doxycycline induction, as well as in FS4, FS5, 1205Lu, FS12, FS14, 
WM164 cells which are known for high or low Wnt5A levels. (D) Immunohistochemistry 




Figure 4 Chemokine expression patterns. 
(A) & (B) Mouse chemokine array analysis of 25 chemokines. Among them, CXCL10, 
CCL2, CXCL1 and CCL5 show the decreased expression levels. (C) RT-PCR analysis 
show the decreased level of CXCL10 and CCL2 transcripts in YUMM1.7 cells after 




Figure 5 RT-PCR analysis of chemokines and cytokines. 
(A) There are no significant changes in the expression of CCL5, CXCL9 and CXCL11. 
(B) Pro-inflammatory cytokines IL-6 and anti-inflammatory cytokine IL-10 showed no 
changes in their expression. IFN-γ and TNF-α were significantly downregulated in the 




Figure 6 The immune infiltration patterns in vivo with the stimulation of rWnt5A. 
(A) & (C) There are significant decreases in Macrophage infiltration to the tumor site 
with the rWnt5A stimulation. (B) & (D) Dendritic cells are less infiltrated into the tumor in 
the rWnt5A treated group. There are no significant changes in CD4+ T cells (E) and 




Figure 7 Flow cytometric analysis of myeloid cells in the mice bone marrow. 
Density plots of windows and gating strategy used for the identification of myeloid cell 
populations in the bone marrow. Subsets of macrophages and dendritic cells were 
identified by MHC class II and co-stimulatory molecule CD86. The migration status was 
examined by the expression of CCR7.
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Figure 8 Flow cytometric analysis of myeloid cells in the mice spleen. 
Density plots of windows and gating strategy used for the identification of myeloid cell 
populations in the bone marrow. Subsets of macrophages and dendritic cells were 
identified by MHC class II and co-stimulatory molecule CD86. The migration status was 
examined by the expression of CCR7.  
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Figure 9 Flow cytometric analysis of lymphoid cells in the mouse bone marrow 
and spleen. 
Density plots of windows and gating strategy used for the identification of immune cell 








Figure 10 Flow cytometric analysis of Regulatory T cells in the blood and spleen.  
Density plots of windows and gating strategy used for the identification of Treg 




Figure 11 Flow cytometric analysis of chemokine receptor expression on the 
identified leukocytes. 
(A) & (C) CCR2 expression on leukocytes in the bone marrow and spleen. (B) & (D) 
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